RT Journal Article
SR Electronic
T1 DPI-221 [4-((α-S)-α-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: A Novel Nonpeptide δ Receptor Agonist Producing Increased Micturition Interval in Normal Rats
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 601
OP 608
DO 10.1124/jpet.105.090498
VO 315
IS 2
A1 Jonathon D. S. Holt
A1 Michael J. Watson
A1 Jane P. Chang
A1 Scott J. O'Neill
A1 Ke Wei
A1 William Pendergast
A1 Peter J. Gengo
A1 Kwen-Jen Chang
YR 2005
UL http://jpet.aspetjournals.org/content/315/2/601.abstract
AB There is a wealth of information from animal models and clinical opioid-analgesic use that indicates a significant role for opioid receptors in the modulation of bladder activity. The novel benzhydrylpiperazine compound DPI-221 [4-((α-S)-α-((2S,5R)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide] was characterized as having δ receptor selectivity using radioligand binding (Ki = 2.0 ± 0.7 nM, δ receptor; 1800 ± 360 nM, μ receptor; and 2300 ± 680 nM, κ receptor), and agonist activity was demonstrated in the mouse isolated vas deferens where DPI-221 inhibited electrically induced contractions with an IC50 value of 88 ± 7.5 nM. In the guinea pig isolated ileum, DPI-221 had no effect on electrically induced contractions at concentrations as high as 1 μM. Sterile saline was infused (7 ml/h) into the bladder of Sprague-Dawley rats, via a transmural catheter; DPI-221 (1.0 to 20 mg/kg p.o.) significantly increased the interval between micturition events, whereas peak void pressure was not significantly decreased by any dose of DPI-221. The micturition effects of 10 mg/kg p.o. DPI-221 were blocked by naltrindole, indicating a δ receptor mechanism of action. In isolated rat bladder strips, DPI-221 was ineffective at relaxing detrusor muscle precontracted with carbachol. The most crucial safety aspect of δ agonist administration is the incidence of seizure-like convulsions in rodents. DPI-221 produced no convulsions at doses up to 100 mg/kg p.o. in mice, although rapid bolus i.v. injection of 5 mg/kg produced convulsions in 3% of mice tested. These findings indicate a good safety profile for DPI-221 administered orally, with potent efficacy in modifying bladder activity. The American Society for Pharmacology and Experimental Therapeutics